- Home
- TWST
as 05-30-2025 11:43am EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2018 |
| Target Price: | $49.10 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.12 - $60.90 | Next Earning Date: | 05-05-2025 |
| Revenue: | $347,680,000 | Revenue Growth: | 25.30% |
| Revenue Growth (this year): | 22.6% | Revenue Growth (next year): | 17.65% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leproust Emily M. | TWST | Chief Executive Officer | May 21 '25 | Sell | $29.75 | 2,802 | $83,351.09 | 649,630 | |
| Laponis Adam | TWST | Chief Financial Officer | May 21 '25 | Sell | $29.75 | 936 | $27,843.19 | 106,018 | |
| Finn Patrick John | TWST | President and COO | May 8 '25 | Sell | $32.31 | 20,000 | $646,260.00 | 242,660 | |
| Cho Dennis | TWST | See Remarks | May 7 '25 | Sell | $32.72 | 5,000 | $163,590.00 | 105,849 | |
| Leproust Emily M. | TWST | Chief Executive Officer | May 5 '25 | Sell | $37.65 | 5,042 | $189,836.34 | 649,630 | |
| Green Paula | TWST | SVP of Human Resources | May 5 '25 | Sell | $37.65 | 1,101 | $41,453.75 | 129,380 | |
| Cho Dennis | TWST | See Remarks | May 5 '25 | Sell | $37.65 | 689 | $25,941.54 | 105,849 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | May 5 '25 | Sell | $37.65 | 162 | $6,099.46 | 51,272 | |
| Finn Patrick John | TWST | President and COO | May 5 '25 | Sell | $37.65 | 2,800 | $105,422.80 | 242,660 | |
| Finn Patrick John | TWST | President and COO | Apr 23 '25 | Sell | $40.00 | 2,058 | $82,309.71 | 242,660 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Twist Bioscience Expands Element Biosciences Partnership for End-to-End NGS Tools
Business Wire
8 days ago
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
Business Wire
15 days ago
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
Business Wire
17 days ago
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insider Monkey
22 days ago
Twist Bioscience Corporation (TWST): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential
MT Newswires
22 days ago
Twist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets
Business Wire
22 days ago
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
Simply Wall St.
24 days ago
Twist Bioscience Second Quarter 2025 Earnings: EPS Misses Expectations
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.